August 1, 2024 08:00 AM EDT

VC firm venBio secures $528M for ‘extremely selective’ fifth fund after recent IPOs, M&A exits

Kyle LaHucik

Senior Reporter

San Francisco-based investment firm venBio plans to back about a dozen new biotech startups over the coming three years with its latest fund, disclosed Thursday …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

VC firm venBio secures $528M for ‘extremely selective’ fifth fund after recent IPOs, M&A exits

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Updated: Pfizer's activist says board must 'hold management accountable' for R&D shortcomings

Ahead of Novo’s CagriSema readout, Lilly returns to a promising new class of obesity drugs

Roche, Genentech end anti-tau Alzheimer’s drug collaboration with UCB

Editas pivots away from ex vivo sickle cell therapy in favor of in vivo approach

Otsuka’s cytokine-targeting drug for IgAN clears Phase 3 hurdle

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

VC firm ven­Bio se­cures $528M for ‘ex­treme­ly se­lec­tive’ fifth fund af­ter re­cent IPOs, M&A ex­its

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

VC firm venBio secures $528M for ‘extremely selective’ fifth fund after recent IPOs, M&A exits